← Lipocine Inc. (LPCN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Lipocine Inc. (LPCN)
Pharmaceutical Preparations · market cap $18M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Lipocine Inc. (LPCN) is a micro-cap pharmaceutical company with an $18M market cap and approximately $5M in cash, representing roughly 6.7 months of runway. Its lead asset LPCN 1154A is in Phase 3 development for postpartum depression, while the pipeline also includes oral testosterone undecanoate (LPCN 1021, Phase 3 for male hypogonadism) and LPCN 1144 (Phase 2 for NASH/liver cirrhosis). The company faces acute financing risk with no catalysts on the public calendar and a history of significant annual cash burn.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LPCN 1144 Formulation A | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
| LPCN 1154A | Phase 3 | Depression, Postpartum |
| LPCN 1144 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| Oral testosterone undecanoate, LPCN 1021 | Phase 3 | Male Hypogonadism |
| LPCN 1148 | Phase 2 | Liver Cirrhosis |
| LPCN 1021 | Phase 3 | Hypogonadism, Male |
Price & technical context
3-month
-21.7%
6-month
-16.4%
12-month
-41.8%
52-wk range
$1.84–$11.26
vs 50-day MA
-14.5%
vs 200-day MA
-57.8%
Realized vol
167.9%
Max drawdown
-83.7%
Daily closes through 2026-10-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LPCN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.